Harrow, Inc. · NASDAQ:HROW
Harrow — H.C. Wainwright 26th Annual Global Investment Conference 2024
14 slides from Harrow's conference presentation, Sep 9, 2024
Slide 1: Harrow – Your patients. Our purpose.
Shey) HARROW Your patients. Our purpose. tui MOI A H.C. Wainwright 26" Annual Global Investment Conference | 8:00 a.m. ET, September 10, 2024 Mark L. Baum Founder and CEO
Slide 2: Safe Harbor
ee Safe Harbor This presentation contains express “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlyin
Slide 3: Investment Highlights
— Investment Highlights 2024 revenue guidance of >$180 million; accelerating in 2H 2024 Aggregate annual revenue run rate potential of $1 billion by 2027: 1. IHEEZO — launched May of 2023; on track for >$100M in annual revenue Leading 2. VEVYE — launched January 2024; on track for >$100M in annual r
Slide 4: Harrow's Ophthalmic Pharmaceutical Brands
Harrow’s Ophthalmic Pharmaceutical Brands IHEEZO loco ge Maxidex’ (boananssxe op seid on (veomycn and pony Bellas fg dexenebasone sorta Sispers) Natacyn’ (netamyein ophthalmic susponsion) 8% = Zz HARROW vévye lexinpamnatiaie erry TobraDex'ST aapalcante wows @Verkazia’ cyclosporine ophthalmic emulsio
Slide 5: Financial Metrics
ee Financial Metrics {in thousanas 2024 Guidance >$180 million $28,119 $130,193 $88,595 $13,017 $72,476 $11,378 $51,165 $48,871 $5,715 $4,583 ai 9 20 2 22 23 24 9 1H24 Consolidated Revenues Adjusted EBITDA) 1 Adjusted EBITDA is defined as net loss, excluding the effects of stock-based compensation a
Slide 6: IHEEZO
— IHEEZO IHEEZO Quarterly Customer Unit Demand* (beginning with May 2023 launch) * Ocular anesthetic gel with a broad indication for all ocular anesthetic use cases * 17+ million annual ophthalmic procedures; 10+ million annual intravitreal injections * Product-specific J-code (J-2403) * Separately
Slide 7: VEVYE
— VEVYE VEVYE Quarterly Prescriptions (beginning with January 2024 launch) (PhilRx Only; Excludes Retail Channel) * Multi-billion dollar U.S. market 29,969 * First and only water-free cyclosporine (0.1%) - approved for signs and symptoms of dry eye disease * Ina pre-clinical ex-vivo corneal penetrat
Slide 8: TRIESENCE
— TRIESENCE Preservative-free triamcinolone acetonide suspension Sterile Key on-label indications!) = Visualization During Vitrectomy (420,000 procedures per year) ei ata] = Posterior Uveitis (100,000 diagnoses per year) injectable suspension 5+ years on FDA's Drug Shortage List; out-of-stock for 2+
Slide 9: Anterior Segment Products
—— Anterior Segment Products Flarex FRESHKOTE” mene Canoe (nepafenac ophthalmic “Workhorse” portfolio includes: ont sear evens eer = Steroids, NSAIDs, and Anti-inflammatories ae Maxidex’ Maxitrol . ive-t ij @Verkazia’ (neomycin and An OTC preservative-free lubricant Maxie cyclosporine ophthalmic pol
Slide 10: ImprimisRx
a ImprimisRx Imprimis 2 Revenues* (Dollars in thousands) = Leading U.S. ophthalmic-focused $82,013 79.935 compounding business $69,104 = More than 15,000 U.S. customers = 50-state dispensing capabilities 7 $51,099 $48,475 = Broad product portfolio wien $02,318 = 10%+ expected 2024 revenue growth $26
Slide 11: MELT-300 Cataract Surgery Sedation Drug Candidate
— MELT-300 Cataract Surgery Sedation Drug Candidate = Melt Pharmaceuticals, a former subsidiary of Harrow * MELT-300 is a non-IV and non-opioid sublingual sedation drug candidate for short-duration medical procedures + MELT-300 is patented in the U.S. and key global markets * Potential impact in >10
Slide 12: Summary
Summary Founder Leadership Harrow’s senior management team is led by its Founders, who are heavily incentivized through their equity ownership and have a strong history of balancing growth while protecting common stockholders HARROW Strong Financial Growth 2024 revenues expected to grow from $130 mi
Slide 13: Harrow
» HARROW 1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 www.Harrow.com Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com Direct: 615-733-4737 Your patients. Our purpose. all 4A A
Slide 14: Appendix — VEVYE Surface Tension
ee Appendix — VEVYE Surface Tension SALINE @ a , a ee ee frase] oe oN y ™~ a a | PERFLUOROBUTYLPENTANE HARROW “ Investor Presentation | September 2024
Harrow — H.C. Wainwright 26th Annual Global Investment Conference 2024 on 6ix